<i>Salmonella</i> and Biotechnology

Abstract

Salmonella strains have been actively studied as live carriers of heterologous antigens for a possible vaccine application. Especially, Salmonella Typhimurium, a facultative anaerobe, has been adapted as an antitumor agent capable of preferentially proliferating within tumors and inhibiting their growth. To enhance the cancer therapeutic efficacy of S. Typhimurium, combinations of gene-directed protein or microRNA therapies and auxotrophic strains of S. Typhimurium have been generated by genetic engineering. Until now, the idea of using bacteria including Salmonella in the treatments of cancer and other diseases has been considered a novel approach. Here, we describe this application based on Salmonella engineering for treatments of cancer or atopic dermatitis.

Bacteria Emerging As an Opportunistic Pathogen

“…It is during an appropriate antibiotic therapy that Salmonellosis relapses in AIDS. In the United States, S. typhimurium and S. enteridis are commonly isolated form the blood of patients with AIDS [30].…”